Blackstone (NYSE:BX) is a leading global investment firm specializing in private equity, real estate, credit, and hedge fund investment strategies. The company is known for its strategic acquisitions and investments across various sectors. Blackstone competes with other major private equity firms like KKR and Carlyle Group.
On October 21, 2025, Morgan Stanley maintained its "Overweight" rating for Blackstone, indicating confidence in the stock's potential to outperform the market. At the time, Blackstone's stock was priced at $161.89. Morgan Stanley also raised Blackstone's price target from $200 to $215, as highlighted by TheFly, suggesting optimism about the company's future performance.
Blackstone's recent agreement with TPG to acquire Hologic, a women's health company, for up to $18.3 billion underscores its strategic focus on the healthcare sector. The deal involves purchasing all outstanding shares at $76 each in cash, highlighting the significant investment interest in healthcare by major private equity firms. This acquisition aligns with Blackstone's strategy to expand its portfolio in high-growth industries.
Currently, Blackstone's stock is trading at $161.67 on the NYSE, reflecting a 0.77% increase or $1.23. The stock has traded between a low of $159.81 and a high of $162.15 today. Over the past year, Blackstone's stock has reached a high of $200.96 and a low of $115.66, indicating significant volatility and potential for growth.
Blackstone's market capitalization is approximately $194 billion, with a trading volume of 522,544 shares. This substantial market cap reflects the company's strong position in the investment industry. The recent acquisition of Hologic is expected to further enhance Blackstone's market presence and drive future growth.
